Anti-XDR-TB drug, anti-MDR-TB drug, and combination anti-tuberculosis drug
AssigneesMicrobial Chemistry Research Foundation, Infectious Disease Research Institute
InventorsYoshiaki Takahashi, Masayuki Igarashi, Masaji Okada
Life of this patent
Estimating the term…
Abstract
A method for treating an individual infected with XDR-TB, the method including administering to the individual an anti-XDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below:
Claims3
A method for treating an individual infected with extensively drug-resistant tuberculosis, the method comprising:
- administering to the individual an anti-extensively drug-resistant tuberculosis drug which comprises a compound having a structure expressed by Structural Formula (1) below:
A method for treating an individual infected with multidrug-resistant tuberculosis, the method comprising:
- administering to the individual an anti-multidrug-resistant tuberculosis drug which comprises a compound having a structure expressed by Structural Formula (1) below:
A method for treating an individual infected with drug-sensitive tuberculosis bacteria, the method comprising:
- administering to the individual a drug, wherein the drug comprises (i) compound having a structure expressed by Structural Formula (1) below:
- and (ii) at least one anti-tuberculosis drug selected from rifampicin (RFP) and isonicotinic acid hydrazide (INH).
Dependencies are inferred from the claim text.